4623-24-9

Usage

Uses

Used in Pharmaceutical Industry:
M-Aminobenzyl Cyanide is used as a key reagent for the synthesis of aminophenylalkylaminopyrrolopyrimidines, which are compounds with significant anti-influenza activity. These synthesized compounds have the potential to inhibit the replication of influenza viruses, making them valuable in the development of new antiviral medications.

InChI:InChI=1/C8H8N2/c9-5-4-7-2-1-3-8(10)6-7/h1-3,6H,4,10H2

Upstream product

• 621-50-1 (3-nitrophenyl)acetonitrile 
• 7647-01-0 hydrogenchloride 
• 619-23-8 3-Nitrobenzyl chloride 
• 105-56-6 ethyl 2-cyanoacetate 
• 108-42-9 3-chloro-aniline 
• 1877-73-2 3-nitro-benzeneacetic acid 
• 5247-25-6 2-(3-nitrophenyl)acetic acid amide 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 25263-44-9 3-Hydroxyphenylacetonitrile 
• 63134-23-6 (3-diethylamino-phenyl)-acetonitrile 
• 408507-75-5 N-(3-cyanomethyl-phenyl)-acetamide 
• 124112-07-8 3-cyanomethyl-tri-N-methyl-anilinium; iodide 
• 1027915-80-5 (3-Amino-phenyl)-pyridin-2-yl-acetonitrile 
• 175696-75-0 2-(3-(pyrrolidin-1-yl)phenyl)acetonitrile 
• 175696-72-7 (3-dimethylamino-phenyl)-acetonitrile 
• 39911-86-9 2-(3-(piperidin-1-yl)phenyl)acetonitrile 
• 76935-75-6 2-(3-aminophenyl)ethylamine 
• 898535-19-8 N-(3-cyanomethyl-phenyl)-benzenesulfonamide 
• 945618-74-6 C₁₉H₂₃N₅O 
• 898534-92-4 N-[3-(2-amino-ethyl)-phenyl]-benzenesulfonamide 
• 898534-91-3 [2-(3-benzenesulfonylamino-phenyl)-ethyl]-carbamic acid ethyl ester 
• 180079-94-1 N-(3-aminophenylmethyl)methylcarbamic acid t-butyl ester 

Relevant academic research and scientific papers

Assembly of α-(Hetero)aryl Nitriles via Copper-Catalyzed Coupling Reactions with (Hetero)aryl Chlorides and Bromides

α-(Hetero)aryl nitriles are important structural motifs for pharmaceutical design. The known methods for direct synthesis of these compounds via coupling with (hetero)aryl halides suffer from narrow reaction scope. Herein, we report that the combination of copper salts and oxalic diamides enables the coupling of a variety of (hetero)aryl halides (Cl, Br) and ethyl cyanoacetate under mild conditions, affording α-(hetero)arylacetonitriles via one-pot decarboxylation. Additionally, the CuBr/oxalic diamide catalyzed coupling of (hetero)aryl bromides with α-alkyl-substituted ethyl cyanoacetates proceeds smoothly at 60 °C, leading to the formation of α-alkyl (hetero)arylacetonitriles after decarboxylation. The method features a general substrate scope and is compatible with various functionalities and heteroaryls.

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors

Development of selective kinase inhibitors remains a challenge due to considerable amino acid sequence similarity among family members particularly in the ATP binding site. Targeting the activation loop might offer improved inhibitor selectivity since this region of kinases is less conserved. However, the strategy presents difficulties due to activation loop flexibility. Herein, we report the design of receptor-interacting protein kinase 2 (RIPK2) inhibitors based on pan-kinase inhibitor regorafenib that aim to engage basic activation loop residues Lys169 or Arg171. We report development of CSR35 that displayed >10-fold selective inhibition of RIPK2 versus VEGFR2, the target of regorafenib. A co-crystal structure of CSR35 with RIPK2 revealed a resolved activation loop with an ionic interaction between the carboxylic acid installed in the inhibitor and the side-chain of Lys169. Our data provides principle feasibility of developing activation loop targeting type II inhibitors as a complementary strategy for achieving improved selectivity.

Preparation method for arylamine compounds

The invention relates to a preparation method for arylamine compounds, belonging to the fields of medical and chemical intermediate and related chemical technologies. The preparation method comprises the following steps: (1) adding nitro-substituted aromatic compounds, a nanometer porous metal catalyst and a solvent into a reaction vessel, introducing hydrogen and carrying out heating and stirring; and (2) after completion of reaction, subjecting a reaction solution obtained in the step (1) to pressure reduction so as to remove the solvent and carrying out column chromatography so as to obtain target products, i.e., the arylamine compounds. Compared with the prior art, the invention has the following advantages: the nanometer porous palladium catalyst used in the method can perform its unique catalytic activity under mild conditions, is convenient to recycle as a catalyst and can be repeatedly used after simple filtering and cleaning; and the catalyst has stable structure and high catalytic activity and is not obviously reduced in catalytic activity after repeated usage, so industrialization of the arylamine compounds is made possible.

Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors

Abstract: Bacterial resistance represents a worldwide emergency threatening the efficacy of all available antibiotics. Among the several resistance mechanisms developed by bacteria, β-lactamase enzymes?(BLs), which are able to inactivate most β-lactam core antibiotics, represent a key target to block, thus prolonging antibiotics half-life. Several approaches aimed at inhibiting β-lactamases have been so far undertaken, mainly involving β-lactam-like or covalent inhibitors. Applying a structure-based de novo design approach, we recently discovered a novel, non-covalent and competitive inhibitor of AmpC β-lactamase:?lead 1. It has a Ki of 1 μM, a ligand efficiency of 0.38 kcal mol?1 and lead-like physical properties. Moreover, it reverts resistance to ceftazidime in bacterial pathogens expressing AmpC and does not up-regulate β-lactamases expression in cell culture. Its features make it a good candidate for chemical optimization: starting from lead 1 crystallographic complex with AmpC, 11 analogs were designed to complement additional AmpC sites, then synthesized and tested against clinically resistant pathogens. While the new inhibitors maintain similar in vitro activity as the starting lead, some of them, in biological assays, extert a higher potency showing improved synergic activity with ceftazidime in resistant clinically isolated strains. Graphical Abstract: [InlineMediaObject not available: see fulltext.].

Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors

Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low

SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN

Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and pro-drugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain)

BORON-CONTAINING SMALL MOLECULES

This invention relates to 6-substituted benzoxaborole compounds of the following formula and their use for treating bacterial infections.

Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use

A method of treatment or prevention of Castleman's disease, atherosclerosis, coronary artery disease, peripheral edema, peripheral vascular disease, glaucoma, and wet or dry age-related macular degeneration (AMD), asthma; chronic bronchitis; chronic obstr

PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.